NCAM1 and small cell lung carcinoma: CD56-CAR-T exhibited significant cytolytic activity against CD56+ SCLC cell lines and other malignancies in vitro and in vivo. CD56 has previously been targeted by antibody-based therapies with proven preclinical efficacy (64).